| 1 |
Fay CJ, Awh KC, LeBoeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2022;12:1071171. [PMID: 36713518 DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
|
| 2 |
Xiao F, Cheng Y, Wang JR, Wang D, Zhang Y, Chen K, Mei X, Luo X. Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement. Pharmaceutics 2022;14:2198. [PMID: 36297633 DOI: 10.3390/pharmaceutics14102198] [Reference Citation Analysis]
|
| 3 |
Nakagawa Y, Hamada T, Hirai Y, Miyake T, Yamasaki O, Iwatsuki K, Morizane S. Efficacy and Safety of Oral Bexarotene for Japanese Patients with Mycosis Fungoides : A Retrospective Case-Series Study of a Single Medical Center in Japan. Nishinihon J Dermatol 2021;83:549-553. [DOI: 10.2336/nishinihonhifu.83.549] [Reference Citation Analysis]
|
| 4 |
Pattan V, Schaab K, Sundaresh V. Bexarotene: A Rare Cause of Misleading Thyroid Function Tests. Cureus 2020;12:e11591. [PMID: 33364113 DOI: 10.7759/cureus.11591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 5 |
Cabello I, Alia P, Pintó X, Muniesa C, Fernandez-de-Misa R, Peñate Y, Morillo M, Perez-Farriols A, Estrach T, Izu R, Gallardo F, Román C, Cervigón I, Ortiz-Brugues A, Ortiz-Romero PL, Servitje O. Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. JAMA Dermatol 2018;154:1424-31. [PMID: 30422238 DOI: 10.1001/jamadermatol.2018.3679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 6 |
Sato Y, Fujimura T, Kambayashi Y, Hashimoto A, Aiba S. Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy. Case Rep Oncol 2018;11:212-5. [PMID: 29681823 DOI: 10.1159/000488236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 7 |
Wang X, Dasari S, Nowakowski GS, Lazaridis KN, Wieben ED, Kadin ME, Feldman AL, Boddicker RL. Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget 2017;8:26245-55. [PMID: 28412739 DOI: 10.18632/oncotarget.15441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 8 |
Tanita K, Fujimura T, Sato Y, Hidaka T, Furudate S, Kambayashi Y, Tsukada A, Hashimoto A, Aiba S. Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy. Case Rep Oncol 2017;10:328-32. [PMID: 28512419 DOI: 10.1159/000468981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Lerner V, McCaffery PJ, Ritsner MS. Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date. CNS Drugs 2016;30:269-80. [PMID: 26968404 DOI: 10.1007/s40263-016-0316-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
